Chromadex Corp (NASDAQ: CDXC) has a higher price-to-earnings ratio of 329.10x compared to its average ratio, The 36-month beta value for CDXC is at 2.16. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CDXC is 48.38M, and currently, shorts hold a 4.13% of that float. The average trading volume for CDXC on December 13, 2024 was 1.22M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CDXC) stock’s latest price update
Chromadex Corp (NASDAQ: CDXC) has seen a decline in its stock price by -2.51 in relation to its previous close of 6.38. However, the company has experienced a -7.44% decline in its stock price over the last five trading sessions. zacks.com reported 2024-12-09 that If you are looking for stocks that are well positioned to maintain their recent uptrend, ChromaDex (CDXC) could be a great choice. It is one of the several stocks that passed through our “Recent Price Strength” screen.
CDXC’s Market Performance
Chromadex Corp (CDXC) has experienced a -7.44% fall in stock performance for the past week, with a -11.27% drop in the past month, and a 81.87% rise in the past quarter. The volatility ratio for the week is 5.61%, and the volatility levels for the past 30 days are at 6.26% for CDXC. The simple moving average for the past 20 days is -13.03% for CDXC’s stock, with a 65.44% simple moving average for the past 200 days.
Analysts’ Opinion of CDXC
B. Riley Securities, on the other hand, stated in their research note that they expect to see CDXC reach a price target of $2.40, previously predicting the price at $6. The rating they have provided for CDXC stocks is “Neutral” according to the report published on August 11th, 2022.
ROTH Capital gave a rating of “Buy” to CDXC, setting the target price at $7 in the report published on March 08th of the previous year.
CDXC Trading at 11.63% from the 50-Day Moving Average
After a stumble in the market that brought CDXC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.99% of loss for the given period.
Volatility was left at 6.26%, however, over the last 30 days, the volatility rate increased by 5.61%, as shares sank -12.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +80.69% upper at present.
During the last 5 trading sessions, CDXC fell by -6.70%, which changed the moving average for the period of 200-days by +275.45% in comparison to the 20-day moving average, which settled at $7.15. In addition, Chromadex Corp saw 334.97% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDXC starting from Pamir Ozan, who purchase 2,907 shares at the price of $7.36 back on Nov 22 ’24. After this action, Pamir Ozan now owns 2,907 shares of Chromadex Corp, valued at $21,397 using the latest closing price.
Patrick Kristin, the Director of Chromadex Corp, sale 23,000 shares at $3.57 during a trade that took place back on Aug 23 ’24, which means that Patrick Kristin is holding 0 shares at $82,110 based on the most recent closing price.
Stock Fundamentals for CDXC
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.56 for the gross margin
The net margin for Chromadex Corp stands at 0.01. The total capital return value is set at 0.06. Equity return is now at value 4.82, with 2.70 for asset returns.
Based on Chromadex Corp (CDXC), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 4.01.
Currently, EBITDA for the company is -3.89 million with net debt to EBITDA at -15.16. When we switch over and look at the enterprise to sales, we see a ratio of 4.43. The receivables turnover for the company is 14.23for trailing twelve months and the total asset turnover is 1.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.95.
Conclusion
In conclusion, Chromadex Corp (CDXC) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
